WO1997039752A1 - Preparation et procede de production du sertindole - Google Patents

Preparation et procede de production du sertindole Download PDF

Info

Publication number
WO1997039752A1
WO1997039752A1 PCT/JP1997/001404 JP9701404W WO9739752A1 WO 1997039752 A1 WO1997039752 A1 WO 1997039752A1 JP 9701404 W JP9701404 W JP 9701404W WO 9739752 A1 WO9739752 A1 WO 9739752A1
Authority
WO
WIPO (PCT)
Prior art keywords
sertindole
titanium oxide
parts
weight
preparation
Prior art date
Application number
PCT/JP1997/001404
Other languages
English (en)
Japanese (ja)
Inventor
Eizou Wakamiya
Yoshikazu Suzuki
Toshihiro Ogura
Hitoshi Kadota
Toshiro Fujii
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to AU24050/97A priority Critical patent/AU2405097A/en
Publication of WO1997039752A1 publication Critical patent/WO1997039752A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds

Definitions

  • the present invention relates to a sertindole preparation having high stability to light, and a method for producing the preparation.
  • Sertindole (Compound name: 5-chloro (4-fluorophenyl) -3- [1- (2-oxoimidazolidin-1-ylethyl) -4-piperidyl] -1H-indole; Described in No. 236 764: International common name (INN): 1- [2- [4- [5-Chloro- (P-fluorophenyl) indole-3-yl] piperidino] ethyl]- 2-imidazolidinone) has both anti-dopamine and anti-serotonin effects and is used as a treatment for schizophrenia.
  • Sertindole is effective in reducing both the positive symptoms of schizophrenia (such as hallucinations and delusions) and the negative symptoms (such as autism, emotions and dementia) even when used in relatively small doses. Have. In addition, sertindole has fewer extrapyramidal side effects such as movement disorders found when using conventional schizophrenia drugs.
  • Japanese Patent Application Laid-Open No. 236 764 describes a sertindole tablet containing lactose and the like.
  • the present inventors have found that such conventional sertindole preparations are unstable to light and are hardly practical. Therefore, in order to provide higher quality sertindol preparations, it is necessary to develop a method for stably storing sertindole.
  • Examples of methods for stably storing a drug that is unstable to light include a method of storing a drug product in a light-shielding bottle, a method of packaging with aluminum foil, and a method of using a packaging material containing an ultraviolet absorber. Is mentioned. However, today ’s drug distribution system and Considering the dispensing work with other drugs in hospitals, these conventional methods are not preferred. Also, considering the stability of the packaged product after the patient has opened it, these conventional methods are not preferable. Disclosure of the invention
  • An object of the present invention is to provide a sertindole preparation having high stability to light.
  • the sertindole preparation of the present invention is coated with a skin containing titanium oxide.
  • the sertindole preparation of the present invention is a fine granule or a granule.
  • the sertindole formulation of the invention is a tablet.
  • the sertindole preparation of the present invention is a forcepsell containing the fine granules or granules of the present invention.
  • the sertindole formulation of the present invention comprises sertindole
  • titanium oxide About 2 to about 200 parts by weight of titanium oxide is contained per 100 parts by weight.
  • the formulation contains about 0.5 to about 50 parts by weight of titanium oxide per 100 parts by weight of the coating.
  • the coating further contains lactose.
  • the coating further contains talc.
  • the formulation contains about 20 to about 200 parts by weight per 100 parts by weight of titanium oxide.
  • the coating composition comprises Sertindole 100 It contains about 2 to about 200 parts by weight of titanium oxide per part by weight.
  • the coating composition further comprises lactose.
  • the coating composition further comprises a bulk.
  • the sertindol preparation is a fine granule
  • the production method comprises mixing a mixed powder containing sertindole and lactose with titanium oxide. Coating with the contained coating composition.
  • the powder mixture contains lactose with a particle size of about 10 wm to about 250.
  • the present inventors have studied the wavelength region of light that affects the degradation of sertindole using a diffraction grating type irradiation spectroscope. As a result, it was found that sertindole was decomposed by light having a wavelength in the ultraviolet region of 350 nm or less, resulting in coloring and a slight decrease in sertindole content.
  • the present inventors attempted to package a sertindole preparation using an ultraviolet ray blocking material.
  • Sertindole tablets were packaged in a polyvinyl chloride packaging material containing an ultraviolet absorber such as a salicylic acid derivative, a benzophenone compound, or a benzotriazole compound.
  • an ultraviolet absorber such as a salicylic acid derivative, a benzophenone compound, or a benzotriazole compound.
  • the stretched portion of the sheet becomes thinner, and the effect of improving the storage stability of tablets by this method is slight.
  • the present inventors studied to impart light-shielding properties to the sertindole preparation itself. Debated. As a result, the present inventors have found that by coating a certindole preparation with a skin containing titanium oxide as a light-shielding agent, sertindole can be stably stored against light, and the present invention has been achieved. It was completed.
  • the titanium oxide used in the present invention may be any of a crystal type such as a rutile type and an analog type, and the grain size is not particularly limited. Titanium oxide is incorporated into the preparation at a ratio of about 2 to about 200 parts by weight, preferably about 5 to about 100 parts by weight per 100 parts by weight of sertindole.
  • the sertindole preparation of the present invention can be a fine granule, granule, tablet or capsule.
  • the definition of each dosage form and each excipient used in this specification basically follows the definition of the Japanese Pharmacopoeia, Twelfth Edition. Hereinafter, the present invention will be described in detail for each dosage form. Fine Granules>
  • Fine granules are preparations that generally pass 10% or less of the total amount through a No. 200 (75 m) sieve.
  • the fine granules of the present invention are usually produced by a fluidized-bed granulation method. Specifically, the mixed powder of sertindole and additives is sieved, and if necessary, granulated with a fluidized bed granulator using lactose nuclei. Clearly, the particles of the mixed powder are coated with particles of the mixed powder using a suspension of titanium oxide (ie, a coating composition) to form a coating on each particle. After the obtained particles are dried and classified, the fine granules of the present invention can be obtained.
  • a suspension of titanium oxide ie, a coating composition
  • additives examples include excipients and binders.
  • excipients lactose, corn starch and the like can be used.
  • binder hydroxybutyl pill cellulose (HPC) is preferably used. Still other commonly used additives may be used.
  • the above-mentioned coating composition may preferably be an aqueous lactose solution in which titanium oxide is dispersed.
  • a certain amount of light-shielding properties can be obtained even by coating using a heat-dissolved lactose aqueous solution containing no titanium oxide together with a binder.
  • the use of titanium oxide reduces lactose coverage, Light shielding properties can be obtained.
  • the addition amount of titanium oxide is preferably about 10 to about 200 parts by weight, more preferably about 40 to about 100 parts by weight, based on 100 parts by weight of sertindole. .
  • the coating composition comprises lactose
  • the lactose content is preferably from about 30 to about 80%, preferably from about 40 to about 70% by weight, based on the total weight of the granule.
  • the titanium oxide is added for the purpose of preventing photodegradation of sertindole contained in the preparation and accompanying yellowing and reduction of sertindole content.
  • the amount of titanium oxide added increased, the resulting fine granules tended to turn blue-gray due to the dawn.
  • talc is preferably about 20 to about 200 parts by weight, more preferably about 50 to about 100 parts by weight, based on 100 parts by weight of titanium oxide.
  • talc discoloration due to titanium oxide in the obtained fine granules can be substantially suppressed.
  • the coating composition contains titanium oxide
  • the light stability of the fine granules can be improved.
  • the use of titanium oxide can reduce the total amount of coating, thereby reducing the time required for granulation.
  • the granulation time can be further reduced by coarsening the particles of the excipient (eg, lactose) contained in the powder mixture.
  • the coating composition may further include pharmaceutically acceptable additives such as a plasticizer, a coloring agent, a lubricant, and the like, if necessary.
  • pharmaceutically acceptable additives such as a plasticizer, a coloring agent, a lubricant, and the like, if necessary.
  • the granules of the present invention may be in any shape such as a sphere, a column, and an irregular shape.
  • the particle size can be any commonly used particle size (eg, about 0.4 to about 2.0 mm in diameter).
  • the granules of the present invention are usually prepared by preparing elementary granules containing sertindole and additives, and then preparing a suspension in which titanium oxide is dispersed (ie, a coating composition). It is obtained by coating granules to form a coating.
  • Raw granules are usually produced by extrusion granulation (using a columnar granule manufacturing device, etc.), crushing granulation, tumbling granulation, fluidized bed granulation, and the like.
  • additives examples include excipients and binders.
  • excipients sucrose, lactose, mannitol and the like can be used.
  • binder hydroxypropylcellulose (HPC), pregelatinized starch and the like can be used. Still other commonly used additives may be used.
  • the elementary granules prepared as described above are coated with a coating composition containing titanium oxide.
  • Coating may be performed by a fluidized bed type coating apparatus.
  • the coating amount is about 2 to about 20 parts by weight (in a dry state), preferably about 5 to about 10 parts by weight, based on 100 parts by weight of the raw granules.
  • the addition amount of titanium oxide is preferably about 5 to about 50 parts by weight, more preferably about 10 parts by weight, based on 100 parts by weight of sertindole.
  • the coating composition may contain a water-soluble polymer in addition to titanium oxide.
  • Water-soluble polymers can be used for film formation.
  • the water-soluble polymer hydroxypropyl methylcellulose (HPMC), hydroxybutyral cellulose (HPC), polyvinylpyrrolidone (PVP) and the like can be used.
  • the addition amount of the water-soluble polymer is about 1 to about 100 parts by weight, preferably about 10 to about 50 parts by weight, based on 10 parts by weight of titanium oxide.
  • the coating composition may preferably further contain talc. As in the case of the fine granules, by adding talc to the coating composition, the discoloration of the granules to blue-grey due to the exposure of the titanium oxide can be suppressed.
  • the amount of talc added is preferably about 50 to about 200 parts by weight, more preferably about 80 to about 150 parts by weight, based on 100 parts by weight of titanium oxide.
  • the coating composition may further include pharmaceutically acceptable additives such as a plasticizer, a coloring agent, a lubricant, and the like, if necessary. Pills>
  • the tablet of the present invention can be obtained by preparing an uncoated tablet containing sertindole. Then coating the uncoated tablet with a suspension in which titanium oxide is dispersed to form a coating.
  • a mixed powder is prepared by adding pharmaceutically acceptable excipients such as excipients, disintegrants, binders, and lubricants to sertindole. After preparing granules from the mixed powder of the lever, the mixed powder or granules are tableted according to a conventional method. When tableting granules prepared from the mixed powder, a lubricant is usually added after preparing the granules.
  • Uncoated tablets can be manufactured by appropriately using conventional equipment such as a commonly used mixer, kneader, granulator, fluidized bed granulator, and tableting machine.
  • lactose corn starch and the like can be used.
  • disintegrant calcium carboxymethylcellulose and the like can be used. Hydroxypropylcellulose can be used as the binder. Magnesium stearate can be used as the lubricant.
  • the uncoated tablet prepared as described above is coated with a coating composition containing titanium oxide to form a coating containing titanium oxide.
  • Coating can be performed by a conventional pan-type coating machine, a ventilation type coating machine or the like.
  • the coating amount is about 0.5 to about 10 parts by weight (preferably in a dry state), preferably about 1 to about 5 parts by weight per 100 parts by weight of the element.
  • the amount of titanium oxide to be added is preferably about 2 to about 50 parts by weight, more preferably about 10 to about 30 parts by weight, based on 100 parts by weight of sertindole.
  • the coating composition may contain a water-soluble polymer in addition to titanium oxide.
  • Water-soluble polymers can be used for film formation.
  • As the water-soluble polymer hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC :), polyvinylpyrrolidone (PVP) and the like can be used.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • PVP polyvinylpyrrolidone
  • the amount of water-soluble polymer It is about 1 to about 100 parts by weight, preferably about 10 to about 50 parts by weight, based on 10 parts by weight of the evening water.
  • the coating composition may preferably further contain talc. By adding talc to the coating composition, discoloration of the tablet to
  • the coating composition may further contain pharmaceutically acceptable additives such as a plasticizer, a coloring agent, a lubricant and the like, if necessary.
  • Capsules containing the sertindole fine granules or granules of the present invention obtained as described above in a capsule are also within the scope of the present invention. Also, a capsule in which the capsule of the capsule itself containing titanium oxide is filled with sertindole and an additive is within the scope of the present invention.
  • the preparations themselves are used as they are, or in ordinary transparent glass bottle or plastic bottle packaging. Can be stored stably. Fine granules or granules can also be applied to a strip package (SP package) made of polyethylene-mixed fan mix. Tablets or capsules can also be packaged in blister overnight in vinyl chloride packaging.
  • SP package strip package
  • a mixture of 5 g of sertindole, 266 g of lactose powder, 15 g of corn starch, and 5 g of hydroxypropylcellulose is charged into a small fluidized bed granulator (UNIGRAD), and 2D0 g of lactose, titanium oxide (T i 0 2 )
  • Spray coating granulation was performed using a 45% by weight aqueous solution containing 4 g and 4 g of talc as a coating composition to obtain a white fine granule.
  • 2% by weight of light caustic anhydride (Carplex 67, Shionogi) was mixed as an antistatic agent. Table 1 shows the composition of the obtained fine granules.
  • a white fine granule was produced in the same manner as in Example 1 except that talc was removed from the coating composition used in Example 1.
  • a white fine granule was produced in the same manner as in Example 1 except that titanium oxide and talc were removed from the coating composition used in Example 1.
  • white fine granules were produced by the extrusion granulation method with the composition shown in Table 1. The equipment and conditions used in each step at this time are shown below.
  • Mouth size ; iQO g X 3
  • Sugar spherical granules (Non-barrel 101, Freund Sangyo) Charge 2 kg into a tumbling fluidized bed, and spray a mixed powder of 300 g of sertindole and 600 g of mannitol, and apply a 10% by weight aqueous solution of hydroxypropyl cellulose. Rolling granulation was performed by spraying 1 kg. Next, the obtained granules were dried to obtain spherical elementary granules containing 10% by weight of sertindole.
  • a 5% by weight aqueous coating solution containing 240 g of hydroxymethyl propyl methylcellulose, 24 g of Macrogol 6000, 80 g of titanium oxide (Freund Corporation, rutile type), and 100 g of talc was applied to a Worth Yuichi type fluidized bed. 100 parts by weight of the above granules were coated in a dry state with 8 parts by weight using a mixing machine.Table 3 below shows the compositions of the components used.
  • the obtained granules were packed in SP and irradiated with a fluorescent lamp (cumulative irradiation amount: 336 ⁇ 10 lex-hours). As a result, no decrease in the content of sertindole and no change in appearance of the packed granules were observed.
  • a 10% aqueous coating solution containing 240 g of hydroxypropyl methylcellulose, 24 g of Macrogol 6000, 80 g of titanium oxide (Freund Corporation, Lutheran type), and 0.01 g of red No. 3 aluminum lake pigment was applied to Hiko Co., Ltd.
  • the above uncoated tablets were coated with 4 mgZ tablets in a dry state using I (Future Int Industry). Table 4
  • the obtained tablets were irradiated with a fluorescent lamp (cumulative irradiation amount: 336 lux 'hours) in an unpackaged state in the same manner as in Example 4. As a result, no decrease in the content of sertindole and no change in appearance of the tablet were observed.
  • Example 5 The uncoated tablets prepared in Example 5 were coated with an ultraviolet absorber (benzotriazo B) in blister-type packaging.
  • the tablets of Example 5 (after coating) and the blister-packed uncoated tablets were irradiated with a fluorescent lamp (cumulative irradiation amount of 336 ⁇ 10 lex's) in the same manner as in Example 4.
  • a fluorescent lamp cumulative irradiation amount of 336 ⁇ 10 lex's
  • a sertindole preparation having high storage stability against light is provided.
  • the sertindole preparation of the present invention has a small decrease in the content during storage and little discoloration due to exposure to light.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation de sertindole très stable à la lumière, dont l'enrobage contient un oxyde de titane faisant office d'agent de protection contre la lumière, ainsi que du talc pour protéger la préparation contre la décoloration due à l'oxyde de titane. Pour produire la préparation, on enrobe une poudre mélangée, des granules ou des comprimés non enrobés contenant du sertindole et un ou plusieurs additifs, avec une composition d'enrobage comprenant de l'oxyde de titane et, si nécessaire, du talc.
PCT/JP1997/001404 1996-04-24 1997-04-23 Preparation et procede de production du sertindole WO1997039752A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24050/97A AU2405097A (en) 1996-04-24 1997-04-23 Sertindole preparation and process for the production thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/102935 1996-04-24
JP10293596 1996-04-24

Publications (1)

Publication Number Publication Date
WO1997039752A1 true WO1997039752A1 (fr) 1997-10-30

Family

ID=14340706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/001404 WO1997039752A1 (fr) 1996-04-24 1997-04-23 Preparation et procede de production du sertindole

Country Status (4)

Country Link
AR (1) AR006816A1 (fr)
AU (1) AU2405097A (fr)
WO (1) WO1997039752A1 (fr)
ZA (1) ZA973433B (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001151671A (ja) * 1999-09-06 2001-06-05 Teikoku Hormone Mfg Co Ltd 突起付き粒子製剤
JP2003509461A (ja) * 1999-09-21 2003-03-11 アストラゼネカ・アクチエボラーグ クエチアピン顆粒
JP2005187339A (ja) * 2003-12-24 2005-07-14 Iwaki Seiyaku Co Ltd 耐光性塩酸テルビナフィンフィルムコート錠
WO2005097104A1 (fr) * 2004-04-08 2005-10-20 Kyowa Hakko Kogyo Co., Ltd. PRÉPARATION PHARMACEUTIQUE SOLIDE CONTENANT UN DÉRIVÉ DE DIBENZ[b,e]OXÉPINE
WO2007065448A1 (fr) * 2005-09-08 2007-06-14 H. Lundbeck A/S Formulation solide stable de sertindole
JP2009073774A (ja) * 2007-09-21 2009-04-09 Takada Seiyaku Kk レボフロキサシン粒状製剤の製造方法及び該方法で得られた粒状製剤
KR101252863B1 (ko) * 2004-04-08 2013-04-09 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
WO2013161103A1 (fr) * 2012-04-26 2013-10-31 持田製薬株式会社 Composition comportant de l'oxyde de titane empêché de changer de couleur
JP2014152142A (ja) * 2013-02-08 2014-08-25 Sanwa Kagaku Kenkyusho Co Ltd ループ利尿薬を有効成分とする医薬製剤
JP2015509941A (ja) * 2012-02-16 2015-04-02 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
JP2017031103A (ja) * 2015-08-03 2017-02-09 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02290872A (ja) * 1989-04-11 1990-11-30 H Lundbeck As ５―クロロ―１―（４―フルオロフェニル）　―３―（１―（２―　（２―イミダゾリジノン―１―イル）エチル）　―４―ピペリジル）―１ｈ―インドールまたはその薬学的に容認できる酸付加塩を使用する方法
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
WO1994018953A1 (fr) * 1993-02-24 1994-09-01 Warner-Jenkinson Company, Inc. Composition de colorant et procede de laquage de pastilles et d'articles similaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02290872A (ja) * 1989-04-11 1990-11-30 H Lundbeck As ５―クロロ―１―（４―フルオロフェニル）　―３―（１―（２―　（２―イミダゾリジノン―１―イル）エチル）　―４―ピペリジル）―１ｈ―インドールまたはその薬学的に容認できる酸付加塩を使用する方法
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
WO1994018953A1 (fr) * 1993-02-24 1994-09-01 Warner-Jenkinson Company, Inc. Composition de colorant et procede de laquage de pastilles et d'articles similaires

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001151671A (ja) * 1999-09-06 2001-06-05 Teikoku Hormone Mfg Co Ltd 突起付き粒子製剤
JP2003509461A (ja) * 1999-09-21 2003-03-11 アストラゼネカ・アクチエボラーグ クエチアピン顆粒
JP2005187339A (ja) * 2003-12-24 2005-07-14 Iwaki Seiyaku Co Ltd 耐光性塩酸テルビナフィンフィルムコート錠
JP5611502B2 (ja) * 2004-04-08 2014-10-22 協和発酵キリン株式会社 ジベンゾ［ｂ，ｅ］オキセピン誘導体を含有する固形製剤
JPWO2005097104A1 (ja) * 2004-04-08 2007-08-16 協和醗酵工業株式会社 ジベンゾ［ｂ，ｅ］オキセピン誘導体を含有する固形製剤
JP2013047231A (ja) * 2004-04-08 2013-03-07 Kyowa Hakko Kirin Co Ltd ジベンゾ［ｂ，ｅ］オキセピン誘導体を含有する固形製剤
KR101252863B1 (ko) * 2004-04-08 2013-04-09 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
WO2005097104A1 (fr) * 2004-04-08 2005-10-20 Kyowa Hakko Kogyo Co., Ltd. PRÉPARATION PHARMACEUTIQUE SOLIDE CONTENANT UN DÉRIVÉ DE DIBENZ[b,e]OXÉPINE
JP2016029063A (ja) * 2004-04-08 2016-03-03 協和発酵キリン株式会社 ジベンゾ［ｂ，ｅ］オキセピン誘導体を含有する固形製剤
WO2007065448A1 (fr) * 2005-09-08 2007-06-14 H. Lundbeck A/S Formulation solide stable de sertindole
EA013167B1 (ru) * 2005-09-08 2010-02-26 Х. Лундбекк А/С Стабильная твёрдая композиция сертиндола
JP2009073774A (ja) * 2007-09-21 2009-04-09 Takada Seiyaku Kk レボフロキサシン粒状製剤の製造方法及び該方法で得られた粒状製剤
JP2015509941A (ja) * 2012-02-16 2015-04-02 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
WO2013161103A1 (fr) * 2012-04-26 2013-10-31 持田製薬株式会社 Composition comportant de l'oxyde de titane empêché de changer de couleur
JP2014152142A (ja) * 2013-02-08 2014-08-25 Sanwa Kagaku Kenkyusho Co Ltd ループ利尿薬を有効成分とする医薬製剤
JP2017031103A (ja) * 2015-08-03 2017-02-09 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体

Also Published As

Publication number Publication date
ZA973433B (en) 1997-12-10
AU2405097A (en) 1997-11-12
AR006816A1 (es) 1999-09-29

Similar Documents

Publication Publication Date Title
EP3409272B1 (fr) Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
TW201509941A (zh) 新穎調配物、包含此調配物之錠劑、其用途及其製備方法
JP5490347B2 (ja) 経口投与用製剤
WO2009101940A1 (fr) Comprimé présentant des propriétés d'élution améliorées
CA2651138C (fr) Composition pharmaceutique
CN111212641A (zh) 阿普斯特的药物组合物
WO1997039752A1 (fr) Preparation et procede de production du sertindole
WO2021165316A1 (fr) Composition pharmaceutique comprenant de la dapagliflozine
MXPA97006053A (en) Compressed trimebutin maleate with lami coating
HU228040B1 (en) Coated trimebutine maleate tablet
JP6007169B2 (ja) アリピプラゾール無水物を含有する固形製剤の製造方法
JP6027710B1 (ja) 糖尿病治療用固形製剤
JPH03500288A (ja) 徐放性ニフェジピン製剤
JP2013010753A (ja) 糖衣製剤及びその製造方法
JP2008094845A (ja) 医薬錠剤
EP2957280B1 (fr) Composition pharmaceutique solide de cytisine et son procédé de préparation
WO2017065623A1 (fr) Composition stable contenant de la vitamine c et du zinc
SI21912A (sl) Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino
JP2003300872A (ja) 被覆固形催眠製剤
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
WO2020111089A1 (fr) Composition pharmaceutique
JP2010001242A (ja) レバミピド固形製剤及びその製造方法
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
JP2018172361A (ja) 光安定性を改善した、デュロキセチンを含有する固形製剤
JP6461496B2 (ja) 解熱鎮痛製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA